Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07373639 · ClinicalTrials.gov registry record
A Long-term Follow-up Study in Patients Who Received BEAM-101
A clinical trial of Sickle Cell Disease and Hemoglobinopathy, sponsored by Beam Therapeutics.
- Recruiting
- Registry status
- 50
- Enrollment target
- 17
- Study locations
NCT07373639: Recruiting study of Sickle Cell Disease and Hemoglobinopathy, sponsored by Beam Therapeutics.
NCT07373639 is a study of Sickle Cell Disease and Hemoglobinopathy that is actively recruiting participants, run by Beam Therapeutics. The registered enrollment target is 50 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (83% lower). The trial reports 17 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07373639, a study of Sickle Cell Disease and Hemoglobinopathy, is actively recruiting participants, sponsored by Beam Therapeutics.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is a Long-term Follow-up (LTFU) study in patients who received BEAM-101 in the parent study (Study BTX-AUT-001). Eligible patients who received BEAM-101 will be asked to participate in this LTFU study prior to completing Study BTX-AUT-001. Patients who enter into this study will be followed for 13 years (a total of 15 years after receiving BEAM-101).
Primary Outcome
Monitor all BEAM-101-related AEs and SAEs through Year 15 post-IMP administration, all SAEs regardless of relatedness through Year 5, new malignancies, new or worsening bone marrow-related hematologic disorders, and all-cause mortality.
Conditions Studied
Interventions
- DRUG Long-Term Follow-up Study of patients who received BEAM-101
Study Locations (17)
Ohio
- University Hospitals Clevland Medical Center - Cleveland
- The Clevland Clinic Foundation - Cleveland
Tennessee
- St. Jude Children's Research Hospital - Memphis
- The Children's Hospital at TriStar Centennial - Nashville
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Phoenix Children's Hospital - Phoenix
Florida
- Mayo Clinic Florida - Jacksonville
Georgia
- Children's Healthcare of Atlanta - Aflac Cancer and Blood Disorders Center- Egleston - Atlanta
Massachusetts
- Boston Children's Hospital - Boston
Michigan
- Henry Ford Cancer Center - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-12-15 |
| Est. Completion | 2043-02-12 |
What NCT07373639 shows while recruiting
NCT07373639 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (83% lower).
The record links to 2 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which Long-Term Follow-up Study of patients who received BEAM-101 is the first listed.
NCT07373639 lists 17 locations in 15 states (Ohio, Tennessee, Alabama).
Frequently Asked Questions
What is clinical trial NCT07373639 about?
NCT07373639 is a clinical study titled "A Long-term Follow-up Study in Patients Who Received BEAM-101". This is a Long-term Follow-up (LTFU) study in patients who received BEAM-101 in the parent study (Study BTX-AUT-001). Eligible patients who received BEAM-101 will be asked to participate in this LTFU study prior to completing Study BTX-AUT-001. Patients who enter into this study will be followed for...
What is the current status of trial NCT07373639?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2025-12-15. Estimated completion is 2043-02-12.
What conditions does trial NCT07373639 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Hemoglobinopathy.
What interventions are being tested in trial NCT07373639?
The interventions under investigation include: Long-Term Follow-up Study of patients who received BEAM-101 (DRUG).
Who is sponsoring clinical trial NCT07373639?
This trial is sponsored by Beam Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07373639 being conducted?
This trial has 17 study locations across Alabama, Arizona, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07373639's enrollment target sits among peer trials
50 106th of 213 higher than 100 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Early Life Exposures Among Children With Sickle Cell Disease
RECRUITING · NA
-
Exercise in Child Health
RECRUITING · NA
-
Sickle Cell Children's Exercise Study (SuCCESs)
RECRUITING · NA
-
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
RECRUITING · Phase 1
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI